| 21111 | Humans (MeSH) |
| 10619 | Male (MeSH) |
| 10382 | Female (MeSH) |
| 8620 | Animals (MeSH) |
| 6709 | Adult (MeSH) |
| 6292 | Middle Aged (MeSH) |
| 4616 | Aged (MeSH) |
| 2856 | Germany (MeSH) |
| 2329 | Mice (MeSH) |
| 2212 | Adolescent (MeSH) |
| 2064 | Treatment Outcome (MeSH) |
| 2020 | Time Factors (MeSH) |
| 1798 | Molecular Sequence Data (MeSH) |
| 1742 | Rats (MeSH) |
| 1502 | Aged, 80 and over (MeSH) |
| 1495 | Child (MeSH) |
| 1250 | Cells, Cultured (MeSH) |
| 1241 | Prospective Studies (MeSH) |
| 1225 | Risk Factors (MeSH) |
| 1188 | Amino Acid Sequence (MeSH) |
| 1103 | Sensitivity and Specificity (MeSH) |
| 1100 | Follow-Up Studies (MeSH) |
| 1007 | Retrospective Studies (MeSH) |
| 941 | Germany (epidemiology) |
| 939 | Base Sequence (MeSH) |
| 909 | Cell Line (MeSH) |
| 908 | Reproducibility of Results (MeSH) |
| 870 | Dose-Response Relationship, Drug (MeSH) |
| 859 | Immunohistochemistry (MeSH) |
| 850 | Child, Preschool (MeSH) |
| 833 | Models, Molecular (MeSH) |
| 799 | Cell Line, Tumor (MeSH) |
| 798 | Mutation (MeSH) |
| 797 | Prognosis (MeSH) |
| 790 | Models, Biological (MeSH) |
| 720 | Magnetic Resonance Imaging (MeSH) |
| 672 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 659 | Algorithms (MeSH) |
| 645 | Kinetics (MeSH) |
| 642 | Infant (MeSH) |
| 641 | Protein Binding (MeSH) |
| 638 | Molecular Structure (MeSH) |
| 576 | Disease Models, Animal (MeSH) |
| 550 | Computer Simulation (MeSH) |
| 539 | Questionnaires (MeSH) |
| 534 | RNA, Messenger (metabolism) |
| 531 | Case-Control Studies (MeSH) |
| 529 | Rats, Wistar (MeSH) |
| 515 | Protein Structure, Tertiary (MeSH) |
| 513 | Signal Transduction (MeSH) |
| 505 | Genotype (MeSH) |
| 502 | Phenotype (MeSH) |
| 498 | Severity of Illness Index (MeSH) |
| 496 | Binding Sites (MeSH) |
| 484 | Phylogeny (MeSH) |
| 484 | Analysis of Variance (MeSH) |
| 483 | Mice, Inbred C57BL (MeSH) |
| 473 | Polymerase Chain Reaction (MeSH) |
| 471 | Pregnancy (MeSH) |
| 468 | Survival Analysis (MeSH) |
| 462 | Age Factors (MeSH) |
| 451 | Infant, Newborn (MeSH) |
| 443 | Blotting, Western (MeSH) |
| 440 | Diagnosis, Differential (MeSH) |
| 424 | Magnetic Resonance Imaging (methods) |
| 419 | Models, Chemical (MeSH) |
| 416 | Swine (MeSH) |
| 415 | Incidence (MeSH) |
| 407 | Transfection (MeSH) |
| 407 | Protein Conformation (MeSH) |
| 406 | Temperature (MeSH) |
| 400 | Cell Proliferation (MeSH) |
| 393 | Risk Assessment (methods) |
| 381 | Sequence Analysis, DNA (MeSH) |
| 381 | Hydrogen-Ion Concentration (MeSH) |
| 373 | History, 20th Century (MeSH) |
| 364 | Predictive Value of Tests (MeSH) |
| 363 | Prevalence (MeSH) |
| 361 | Sequence Homology, Amino Acid (MeSH) |
| 360 | Cohort Studies (MeSH) |
| 357 | Ligands (MeSH) |
| 353 | Gene Expression Profiling (MeSH) |
| 352 | Sequence Alignment (MeSH) |
| 352 | Rats, Sprague-Dawley (MeSH) |
| 350 | Tomography, X-Ray Computed (MeSH) |
| 349 | Risk Assessment (MeSH) |
| 349 | Mice, Knockout (MeSH) |
| 346 | Species Specificity (MeSH) |
| 346 | Phosphorylation (MeSH) |
| 346 | Image Processing, Computer-Assisted (MeSH) |
| 344 | Reference Values (MeSH) |
| 344 | Disease Progression (MeSH) |
| 342 | Cattle (MeSH) |
| 339 | RNA, Messenger (genetics) |
| 338 | Cross-Sectional Studies (MeSH) |
| 337 | Statistics, Nonparametric (MeSH) |
| 329 | Oxidation-Reduction (MeSH) |
| 329 | Chronic Disease (MeSH) |
| 328 | DNA Primers (MeSH) |
| 327 | Flow Cytometry (MeSH) |
| 316 | Equipment Design (MeSH) |
| 315 | Survival Rate (MeSH) |
| 313 | Software (MeSH) |
| 313 | Sex Factors (MeSH) |
| 313 | Gene Expression Regulation (MeSH) |
| 310 | Gene Expression (MeSH) |
| 310 | Crystallography, X-Ray (MeSH) |
| 309 | Practice Guidelines as Topic (MeSH) |
| 305 | Transcription, Genetic (MeSH) |
| 303 | Cloning, Molecular (MeSH) |
| 296 | Neoplasm Staging (MeSH) |
| 291 | Recurrence (MeSH) |
| 288 | Calcium (metabolism) |
| 288 | Brain (metabolism) |
| 286 | Enzyme Inhibitors (pharmacology) |
| 285 | Signal Transduction (physiology) |
| 285 | Double-Blind Method (MeSH) |
| 284 | Oligonucleotide Array Sequence Analysis (MeSH) |
| 284 | Brain Mapping (MeSH) |
| 278 | Models, Statistical (MeSH) |
| 278 | Acute Disease (MeSH) |
| 275 | Comorbidity (MeSH) |
| 274 | Quality of Life (MeSH) |
| 274 | Combined Modality Therapy (MeSH) |
| 274 | Apoptosis (MeSH) |
| 273 | Surface Properties (MeSH) |
| 272 | Polymorphism, Genetic (MeSH) |
| 269 | Promoter Regions, Genetic (MeSH) |
| 268 | Transcription Factors (genetics) |
| 267 | Bacterial Proteins (metabolism) |
| 266 | Structure-Activity Relationship (MeSH) |
| 265 | Enzyme-Linked Immunosorbent Assay (MeSH) |
| 265 | Clinical Trials as Topic (MeSH) |
| 262 | Bacterial Proteins (genetics) |
| 261 | Transcription Factors (metabolism) |
| 257 | Europe (MeSH) |
| 255 | Neurons (metabolism) |
| 251 | Mice, Transgenic (MeSH) |
| 251 | Magnetic Resonance Spectroscopy (MeSH) |
| 250 | Apoptosis (drug effects) |
| 247 | Membrane Proteins (metabolism) |
| 245 | Models, Theoretical (MeSH) |
| 242 | RNA, Messenger (analysis) |
| 242 | Catalysis (MeSH) |
| 239 | Mice, Inbred BALB C (MeSH) |
| 239 | Chromatography, High Pressure Liquid (MeSH) |
| 237 | Pilot Projects (MeSH) |
| 236 | Membrane Proteins (genetics) |
| 234 | Microscopy, Fluorescence (MeSH) |
| 233 | T-Lymphocytes (immunology) |
| 232 | Cell Differentiation (MeSH) |
| 231 | Drug Therapy, Combination (MeSH) |
| 230 | Cell Membrane (metabolism) |
| 229 | Models, Genetic (MeSH) |
| 228 | Substrate Specificity (MeSH) |
| 225 | Up-Regulation (MeSH) |
| 225 | Genetic Variation (MeSH) |
| 224 | Recombinant Proteins (metabolism) |
| 224 | History, 19th Century (MeSH) |
| 223 | Feasibility Studies (MeSH) |
| 222 | Evolution, Molecular (MeSH) |
| 222 | DNA-Binding Proteins (metabolism) |
| 219 | Stereoisomerism (MeSH) |
| 219 | Alleles (MeSH) |
| 218 | Thermodynamics (MeSH) |
| 215 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 214 | HeLa Cells (MeSH) |
| 212 | Proteins (chemistry) |
| 211 | Molecular Conformation (MeSH) |
| 211 | DNA Mutational Analysis (MeSH) |
| 210 | Tumor Cells, Cultured (MeSH) |
| 210 | Mutation (genetics) |
| 210 | DNA-Binding Proteins (genetics) |
| 208 | Gene Expression Regulation, Neoplastic (MeSH) |
| 205 | Cell Proliferation (drug effects) |
| 200 | Neurons (physiology) |
| 198 | Light (MeSH) |
| 196 | Data Interpretation, Statistical (MeSH) |
| 195 | Brain (pathology) |
| 195 | Antineoplastic Agents (therapeutic use) |
| 193 | Administration, Oral (MeSH) |
| 192 | Polymerase Chain Reaction (methods) |
| 192 | Drug Administration Schedule (MeSH) |
| 191 | Stents (MeSH) |
| 191 | Materials Testing (MeSH) |
| 190 | Peptides (chemistry) |
| 190 | Microscopy, Confocal (MeSH) |
| 189 | Biological Markers (blood) |
| 188 | Particle Size (MeSH) |
| 187 | Electrophoresis, Polyacrylamide Gel (MeSH) |
| 186 | Water (chemistry) |
| 186 | Cricetinae (MeSH) |
| 185 | Rabbits (MeSH) |
| 185 | Neuropsychological Tests (MeSH) |
| 185 | Dimerization (MeSH) |
| 182 | Regression Analysis (MeSH) |
| 182 | Recombinant Fusion Proteins (metabolism) |
| 182 | Mass Spectrometry (MeSH) |
| 182 | Immunohistochemistry (methods) |
| 182 | Functional Laterality (physiology) |
| 182 | Disease-Free Survival (MeSH) |
| 182 | Animals, Newborn (MeSH) |
| 181 | Contrast Media (MeSH) |
| 181 | Bacterial Proteins (chemistry) |
| 178 | Reaction Time (physiology) |
| 176 | Body Mass Index (MeSH) |
| 175 | Genetic Predisposition to Disease (MeSH) |
| 175 | Escherichia coli (genetics) |
| 174 | Tissue Distribution (MeSH) |
| 174 | Electrocardiography (MeSH) |
| 173 | Multivariate Analysis (MeSH) |
| 173 | Enzyme Activation (MeSH) |
| 172 | In Situ Hybridization, Fluorescence (MeSH) |
| 172 | Gene Frequency (MeSH) |
| 169 | Protein Structure, Secondary (MeSH) |
| 169 | Models, Animal (MeSH) |
| 169 | Dogs (MeSH) |
| 169 | Brain (physiology) |
| 168 | Recombinant Proteins (genetics) |
| 168 | Imaging, Three-Dimensional (MeSH) |
| 167 | Psychomotor Performance (physiology) |
| 167 | Biopsy (MeSH) |
| 166 | Apoptosis (physiology) |
| 165 | User-Computer Interface (MeSH) |
| 165 | United States (MeSH) |
| 165 | Down-Regulation (MeSH) |
| 164 | Tomography, X-Ray Computed (methods) |
| 163 | Protein Folding (MeSH) |
| 163 | Forecasting (MeSH) |
| 163 | DNA (chemistry) |
| 163 | Cell Nucleus (metabolism) |
| 162 | Electroencephalography (MeSH) |
| 161 | Solubility (MeSH) |
| 160 | Polymorphism, Single Nucleotide (MeSH) |
| 160 | Gene Deletion (MeSH) |
| 159 | Stress, Mechanical (MeSH) |
| 159 | Recombinant Proteins (chemistry) |
| 158 | Escherichia coli (metabolism) |
| 158 | Breast Neoplasms (pathology) |
| 157 | Gene Expression Regulation, Developmental (MeSH) |
| 156 | Proteins (metabolism) |
| 156 | Biomechanical Phenomena (MeSH) |
| 153 | Protein Transport (MeSH) |
| 153 | Mutagenesis, Site-Directed (MeSH) |
| 152 | Microscopy, Electron, Scanning (MeSH) |
| 152 | Longitudinal Studies (MeSH) |
| 152 | Liver (metabolism) |
| 151 | In Situ Hybridization (MeSH) |
| 150 | Chromosome Mapping (MeSH) |
| 149 | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization (MeSH) |
| 148 | Statistics as Topic (MeSH) |
| 148 | Drug Interactions (MeSH) |
| 148 | Biological Transport (MeSH) |
| 147 | RNA, Messenger (biosynthesis) |
| 147 | Nerve Tissue Proteins (metabolism) |
| 147 | Image Processing, Computer-Assisted (methods) |
| 146 | Electrophysiology (MeSH) |
| 146 | Cell Survival (drug effects) |
| 145 | Immunosuppressive Agents (therapeutic use) |
| 144 | Patch-Clamp Techniques (MeSH) |
| 143 | Photic Stimulation (MeSH) |
| 142 | Genetic Vectors (MeSH) |
| 142 | Cercopithecus aethiops (MeSH) |
| 141 | Green Fluorescent Proteins (genetics) |
| 141 | Dose-Response Relationship, Radiation (MeSH) |
| 141 | Carrier Proteins (metabolism) |
| 141 | Antineoplastic Agents (pharmacology) |
| 140 | Green Fluorescent Proteins (metabolism) |
| 139 | Aging (physiology) |
| 138 | Gene Expression Regulation (physiology) |
| 137 | Signal Transduction (drug effects) |
| 137 | Randomized Controlled Trials as Topic (MeSH) |
| 137 | Psychiatric Status Rating Scales (MeSH) |
| 137 | Image Enhancement (methods) |
| 136 | Pedigree (MeSH) |
| 136 | Dendritic Cells (immunology) |
| 136 | Cross-Over Studies (MeSH) |
| 136 | Caspases (metabolism) |
| 136 | Brain (physiopathology) |
| 135 | Recombinant Fusion Proteins (genetics) |
| 135 | Physician's Practice Patterns (MeSH) |
| 134 | Nuclear Proteins (genetics) |
| 134 | Biological Evolution (MeSH) |
| 133 | Ultraviolet Rays (MeSH) |
| 133 | Oxygen (blood) |
| 133 | Nuclear Proteins (metabolism) |
| 132 | Molecular Weight (MeSH) |
| 132 | Models, Neurological (MeSH) |
| 132 | Cytokines (metabolism) |
| 132 | Adsorption (MeSH) |
| 131 | Imaging, Three-Dimensional (methods) |
| 130 | Ecosystem (MeSH) |
| 129 | Mitochondria (metabolism) |
| 129 | Membrane Glycoproteins (metabolism) |
| 129 | Gene Expression Regulation, Bacterial (MeSH) |
| 129 | Equipment Failure Analysis (MeSH) |
| 129 | Age Distribution (MeSH) |
| 128 | Polymers (chemistry) |
| 128 | Oxygen (metabolism) |
| 128 | Microscopy, Electron (MeSH) |
| 127 | Random Allocation (MeSH) |
| 127 | Gene Expression Regulation (drug effects) |
| 126 | Saccharomyces cerevisiae Proteins (metabolism) |
| 126 | Logistic Models (MeSH) |
| 126 | COS Cells (MeSH) |
| 125 | Reverse Transcriptase Polymerase Chain Reaction (methods) |
| 125 | Reoperation (MeSH) |
| 125 | Image Interpretation, Computer-Assisted (methods) |
| 125 | Cluster Analysis (MeSH) |
| 125 | Attention (physiology) |
| 124 | Registries (MeSH) |
| 124 | Postoperative Complications (MeSH) |
| 124 | Chi-Square Distribution (MeSH) |
| 124 | Cell Differentiation (physiology) |
| 124 | Antibodies, Monoclonal (therapeutic use) |
| 123 | Neurons (cytology) |
| 123 | Arabidopsis (genetics) |
| 123 | Anti-Bacterial Agents (pharmacology) |
| 122 | Reaction Time (MeSH) |
| 122 | Radiopharmaceuticals (diagnostic use) |
| 122 | RNA Interference (MeSH) |
| 122 | Probability (MeSH) |
| 122 | Neurons (drug effects) |
| 122 | Cell Survival (MeSH) |
| 121 | Patient Satisfaction (MeSH) |
| 121 | Hot Temperature (MeSH) |
| 121 | Fibroblasts (metabolism) |
| 121 | DNA (metabolism) |
| 120 | Promoter Regions, Genetic (genetics) |
| 120 | Microbial Sensitivity Tests (MeSH) |
| 120 | Biological Markers (MeSH) |
| 119 | Microscopy, Electron, Transmission (MeSH) |
| 119 | Genes, Reporter (MeSH) |
| 119 | Crystallization (MeSH) |
| 118 | Nucleic Acid Conformation (MeSH) |
| 118 | Internet (MeSH) |
| 118 | Disability Evaluation (MeSH) |
| 117 | Sex Distribution (MeSH) |
| 117 | DNA (genetics) |
| 117 | Biodegradation, Environmental (MeSH) |
| 117 | Amino Acid Substitution (MeSH) |
| 116 | Radiation Dosage (MeSH) |
| 116 | Phantoms, Imaging (MeSH) |
| 116 | Observer Variation (MeSH) |
| 116 | Nerve Tissue Proteins (genetics) |
| 116 | National Health Programs (economics) |
| 116 | Coronary Angiography (MeSH) |
| 115 | Risk (MeSH) |
| 115 | Artifacts (MeSH) |
| 114 | Hydrogen Bonding (MeSH) |
| 114 | Genetic Markers (MeSH) |
| 114 | Fatal Outcome (MeSH) |
| 114 | Carrier Proteins (genetics) |
| 113 | Trans-Activators (metabolism) |
| 113 | Pain Measurement (MeSH) |
| 113 | Exons (MeSH) |
| 113 | Culture Media (MeSH) |
| 112 | Oligonucleotide Array Sequence Analysis (methods) |
| 112 | Mass Spectrometry (methods) |
| 112 | Gene Expression Profiling (methods) |
| 112 | Blood Pressure (drug effects) |
| 111 | Saccharomyces cerevisiae (genetics) |
| 111 | Protein-Serine-Threonine Kinases (metabolism) |
| 111 | Lasers (MeSH) |
| 111 | Health Status (MeSH) |
| 111 | Fluorescent Antibody Technique (MeSH) |
| 111 | Drug Design (MeSH) |
| 111 | DNA, Complementary (genetics) |
| 111 | Calibration (MeSH) |
| 110 | Spectrometry, Fluorescence (MeSH) |
| 110 | Plant Proteins (metabolism) |
| 110 | Nucleic Acid Hybridization (MeSH) |
| 110 | Diffusion (MeSH) |
| 110 | Conserved Sequence (MeSH) |
| 109 | Positron-Emission Tomography (MeSH) |
| 109 | Photic Stimulation (methods) |
| 109 | Neoplasm Invasiveness (MeSH) |
| 109 | Membrane Glycoproteins (genetics) |
| 109 | Linear Models (MeSH) |
| 109 | Chromatography, High Pressure Liquid (methods) |
| 108 | Syndrome (MeSH) |
| 108 | Infusions, Intravenous (MeSH) |
| 108 | Immunoblotting (MeSH) |
| 107 | Environmental Monitoring (methods) |
| 107 | Cell Movement (MeSH) |
| 107 | Cell Adhesion (MeSH) |
| 107 | CHO Cells (MeSH) |
| 106 | Endothelial Cells (metabolism) |
| 106 | Electric Stimulation (MeSH) |
| 106 | Cost-Benefit Analysis (MeSH) |
| 106 | Computational Biology (MeSH) |
| 105 | Seasons (MeSH) |
| 105 | Saccharomyces cerevisiae (metabolism) |
| 105 | Rats, Inbred Lew (MeSH) |
| 105 | Prosthesis Design (MeSH) |
| 105 | Neoplasm Metastasis (MeSH) |
| 105 | Endothelium, Vascular (cytology) |
| 105 | Electrophoresis, Gel, Two-Dimensional (MeSH) |
| 105 | Cerebral Cortex (physiology) |
| 105 | Area Under Curve (MeSH) |
| 105 | Actins (metabolism) |
| 104 | Proteins (genetics) |
| 104 | Myocardium (metabolism) |
| 104 | Lymphatic Metastasis (MeSH) |
| 104 | Chromosome Aberrations (MeSH) |
| 104 | Anti-Bacterial Agents (therapeutic use) |
| 103 | Visual Perception (physiology) |
| 103 | Tumor Markers, Biological (metabolism) |
| 103 | Stem Cells (cytology) |
| 103 | RNA, Ribosomal, 16S (genetics) |
| 103 | NF-kappa B (metabolism) |
| 103 | Membrane Proteins (chemistry) |
| 103 | Cell Count (MeSH) |
| 102 | Quality Control (MeSH) |
| 102 | Immunoprecipitation (MeSH) |
| 102 | Hydrolysis (MeSH) |
| 102 | Evoked Potentials (physiology) |
| 102 | Environmental Monitoring (MeSH) |
| 102 | CD4-Positive T-Lymphocytes (immunology) |
| 102 | Age of Onset (MeSH) |
| 101 | Radiotherapy Dosage (MeSH) |
| 101 | Genome (MeSH) |
| 101 | Diet (MeSH) |
| 101 | CD8-Positive T-Lymphocytes (immunology) |
| 100 | Haplotypes (MeSH) |
| 100 | Databases, Factual (MeSH) |
| 100 | DNA, Bacterial (genetics) |
| 100 | DNA Damage (MeSH) |
| 100 | Amino Acid Motifs (MeSH) |
| 99 | Positron-Emission Tomography (methods) |
| 99 | Gas Chromatography-Mass Spectrometry (MeSH) |
| 99 | DNA Methylation (MeSH) |
| 98 | Oxidative Stress (MeSH) |
| 98 | Multigene Family (MeSH) |
| 97 | Saccharomyces cerevisiae Proteins (genetics) |
| 97 | Quality Assurance, Health Care (MeSH) |
| 97 | Pressure (MeSH) |
| 97 | Magnetic Resonance Spectroscopy (methods) |
| 97 | Liver (pathology) |
| 97 | Glucose (metabolism) |
| 97 | Escherichia coli Proteins (metabolism) |
| 97 | Drug Combinations (MeSH) |
| 97 | Cytoplasm (metabolism) |
| 96 | Research Design (MeSH) |
| 96 | Reference Standards (MeSH) |
| 96 | Protons (MeSH) |
| 96 | Gene Expression Regulation, Plant (MeSH) |
| 96 | B-Lymphocytes (immunology) |
| 95 | Point Mutation (MeSH) |
| 95 | Nitric Oxide (metabolism) |
| 94 | Tumor Necrosis Factor-alpha (metabolism) |
| 94 | Membrane Potentials (physiology) |
| 94 | Heart Rate (physiology) |
| 94 | Blood Pressure (physiology) |
| 93 | Recombinant Proteins (MeSH) |
| 93 | Proto-Oncogene Proteins (metabolism) |
| 93 | Mice, Nude (MeSH) |
| 93 | Epithelial Cells (metabolism) |
| 93 | DNA, Complementary (metabolism) |
| 93 | Blotting, Northern (MeSH) |
| 92 | Trans-Activators (genetics) |
| 92 | Spectrometry, Mass, Electrospray Ionization (MeSH) |
| 92 | Reactive Oxygen Species (metabolism) |
| 92 | Polymorphism, Restriction Fragment Length (MeSH) |
| 92 | Movement (physiology) |
| 92 | Lymphocyte Activation (MeSH) |
| 92 | Kidney (metabolism) |
| 92 | Computational Biology (methods) |
| 92 | Biological Markers (analysis) |
| 91 | Signal Processing, Computer-Assisted (MeSH) |
| 91 | Neoplasm Proteins (genetics) |
| 91 | DNA, Bacterial (analysis) |
| 90 | Sheep (MeSH) |
| 90 | Organometallic Compounds (chemistry) |
| 90 | Memory (physiology) |
| 90 | Health Surveys (MeSH) |
| 90 | Elasticity (MeSH) |
| 90 | Cell Culture Techniques (MeSH) |
| 90 | Breast Neoplasms (genetics) |
| 90 | Adenocarcinoma (pathology) |
| 89 | Transplantation, Homologous (MeSH) |
| 89 | Recombination, Genetic (MeSH) |
| 89 | Plant Proteins (genetics) |
| 89 | Odds Ratio (MeSH) |
| 89 | Neoplasm Proteins (metabolism) |
| 89 | Information Storage and Retrieval (methods) |
| 89 | Fluorescent Dyes (MeSH) |
| 89 | Electroencephalography (methods) |
| 89 | Data Collection (MeSH) |
| 88 | Patient Selection (MeSH) |
| 88 | Functional Laterality (MeSH) |
| 88 | Arabidopsis (metabolism) |
| 87 | Water Pollutants, Chemical (analysis) |
| 87 | Repressor Proteins (metabolism) |
| 87 | Demography (MeSH) |
| 87 | Cues (MeSH) |
| 87 | Carcinoma, Squamous Cell (pathology) |
| 87 | Adenosine Triphosphate (metabolism) |
| 86 | Sequence Homology, Nucleic Acid (MeSH) |
| 86 | Postoperative Period (MeSH) |
